Header Ab 729


AB-729 is our RNAi therapeutic

AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen (HBsAg), which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using our novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology.

Clinical data to-date

Clinical data generated thus far has shown AB-729 to be generally safe and well-tolerated and to provide a robust and comparable decline in hepatitis B surface antigen and HBV DNAin patients regardless of dose, dosing interval or baseline characteristics. In addition, AB-729 continues to result in HBV-specific T-cell immune restoration and decrease of exhausted T-cells. AB-729 is currently in multiple Phase 2a clinical trials in combination with other antiviral agents for the treatment of cHBV.

We believe AB-729 may have the following important advantages over other RNAi therapeutics and/or standard of care:

  • Less frequent dosing
  • Potential for shorter course therapy

Learn more about AB-729 in practice.